Core Viewpoint - The CRO and CDMO sectors are experiencing a collective rise in stock prices, driven by a combination of recovering demand and supply-side improvements, with expectations for profitability and valuation to increase simultaneously, referred to as a "Davis Double Play" [1][2] Group 1: Stock Performance - Key stocks in the CRO sector have seen significant gains, with Kelaiying up 6.27% to HKD 82.2, Tigermed up 5.48% to HKD 48.92, and Zhaoyan New Drug up 5.19% to HKD 23.52 [1] - Other notable increases include Kanglong Chemical up 3.37% to HKD 22.68 and WuXi AppTec up 3.12% to HKD 109.1 [1] Group 2: Industry Outlook - According to Zhongtai Securities, the CRO and CDMO industries are expected to benefit from a combination of external and internal demand recovery, with supply gradually clearing [1] - The anticipated easing of monetary policy in late 2024 and subsequent geopolitical negotiations in 2025 are expected to improve market sentiment and drive demand recovery [1] - The industry is projected to see significant policy support and the realization of large-scale domestic innovative drug business development starting in 2025 [1] Group 3: Order Growth and Market Dynamics - Industrial insights from Xingye Securities indicate that many CROs are experiencing accelerated order signing, with project volumes achieving double-digit growth [2] - There is a noted upward trend in pricing for experimental monkeys, safety evaluation quotes, and clinical project costs since Q4, reflecting strong customer demand [2] - The global positioning of Chinese CDMOs in the supply chain remains irreplaceable, and the anticipated Federal Reserve interest rate cuts are expected to boost early-stage global R&D demand [2]

Group 1 - The CRO concept stocks have collectively risen, with notable increases in share prices for companies such as Kintor Pharmaceutical (6.27% increase), Tigermed (5.48% increase), and WuXi AppTec (3.12% increase) [1] - Zhongtai Securities believes that the CRO and CDMO industries are experiencing a resonance in both domestic and foreign demand, with a gradual clearing of supply [1] - The demand side is expected to gradually recover due to multiple factors, including the onset of overseas interest rate cuts in Q4 2024, improved pessimistic expectations from geopolitical negotiations in Q2 2025, and the rollout of major domestic innovative drug business development [1] Group 2 - Industrial growth in the CRO sector is being driven by the overseas expansion of innovative drug business development and a stabilization in financing, leading to a double-digit growth in new orders [2] - There is a rising trend in pricing for experimental monkeys, safety evaluation quotes, and clinical project prices since Q4, indicating strong customer demand [2] - The global position of Chinese CDMO in the supply chain is deemed irreplaceable, and the anticipated interest rate cuts by the Federal Reserve are expected to boost early-stage global research and development demand [2]

药明康德（603259）(02359)发布公告，公司于2026年1月5日收到实际控制人控制的股东发出的《告知 函》，截至2026年1月5日，实际控制人控制的股东通过集中竞价和大宗交易方式累计减持公司A股股份 5967.51万股，占公司总股本的2%。本次减持计划已实施完毕。 ...

Industry News - The Ministry of Commerce of China announced strengthened export controls on dual-use items to Japan, effective immediately, due to Japan's recent provocative statements regarding Taiwan, which violate the One China principle [2] - The 2026 National Foreign Exchange Management Work Conference will be held on January 5-6, focusing on optimizing trade foreign exchange management and supporting the development of new trade formats like cross-border e-commerce [3] - Star River Dynamics is set to launch the "Vesta-1 Sea Launch" commercial rocket mission soon [4] - The China Securities Index announced adjustments to the samples of the CSI 1000, CSI 500, and CSI A500 indices, effective after market close on January 9, 2026, with several companies being added and removed from these indices [4] Company News - Jia Mei Packaging announced a cumulative increase of 230% in stock price from December 17, 2025, to January 6, 2026, and will be suspended for verification [8] - Guosheng Technology reported a cumulative increase of 370.2% in stock price from October 31, 2025, to January 6, 2026, and will also be suspended for verification [8] - Brain-computer interface "unicorn" Qiangna Technology completed approximately 2 billion yuan in financing [9] - Chip Origin announced the completion of the acquisition of Zhudian Semiconductor [9] - Puni Testing expects a loss for the entire year of 2025 [9] - WuXi AppTec announced that 18 shareholders reduced their holdings by 2% from November 20, 2025, to January 5, 2026, and this reduction plan has been completed [9] - Super Electronics announced an increase in investment for its AI computing high-end printed circuit board expansion project from 1.468 billion yuan to 3.315 billion yuan [10]

证券代码：603259 证券简称：药明康德 公告编号：临 2026-001 无锡药明康德新药开发股份有限公司股东减持股份结果公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 公司董事会及全体董事保证公告内容与相关股东提供的信息一致。 ■ 注1：上述持股比例按照本公告日公司总股本2,983,757,155股为基础计算。 重要内容提示： ● 股东持股的基本情况 根据无锡药明康德新药开发股份有限公司（以下简称"公司"）于2025年10月30日披露的《股东减持股份 计划公告》（公告编号：临2025-070），本次减持计划实施前公司实际控制人控制的股东合计持有公司 A股股份543,364,675股，占公司总股本的18.211%。该等股份均为公司首次公开发行A股股票并上市前所 取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限售条件流通股。 ● 减持计划的实施结果情况 公司于2026年1月5日收到实际控制人控制的股东发出的《告知函》，截至2026年1月5日，实际控制人控 制的股东通过集中竞价和大宗交易方式累计减持公司股份59,675,143股，占公司总股本的2%。本 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据统计，1月6日，暂无A股上市公司披露增持情况。包括恒宝股份（维权）、山外山、东方中科、盟科 药业、盛科通信、天能重工、燕东微、西部材料、蜀道装备、先锋电子、和而泰、智能自控、银邦股 份、四方精创、福莱蒽特、振华风光、麦克奥迪、农心科技、福立旺、亚威股份、浙江荣泰、宏盛股 份、同洲电子、新金路、西部黄金、金海通、和泰机电、腾景科技、神通科技、药明康德在内的30家A 股上市公司披露减持情况。 | | | 1.6上市公司盘后减持情况 | | --- | --- | --- | | 1 | 恒宝股份 | 控股股东钱京拟减持不超3%公司股份 | | 2 | 山外山 | 股东拟合计减持不超2.00%股份 | | 3 | 盟科药业 | 股东盟科香港拟减持不超3%股份 | | 4 | 东方中科 | 股东大连金投拟减持不超3.00%股份 | | 5 | 盛科通信 | 第二大股东大基金拟减持不超3%股份 | | 6 | 燕矢微 | 第四大股东大基金1月6日减持109.02万股公司股 ...

Group 1 - WuXi AppTec's third, fourth, and sixth largest shareholders reduced their holdings by 2% from November 20, 2025, to January 5, 2026, totaling 59.6751 million shares at prices ranging from 84.66 to 95.08 CNY per share [1] Group 2 - Robotech's subsidiary ficonTEC signed a significant contract worth approximately 770,000 euros (about 63.0784 million CNY) with a Swiss client, representing over 5.70% of the company's audited revenue for 2024 [2] Group 3 - Times New Material signed a sales contract for wind turbine blades worth approximately 3.32 billion CNY, effective from October 1, 2025, to December 31, 2025, which is expected to positively impact the company's performance [3] Group 4 - YHLO signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products, leveraging both companies' resources [4] Group 5 - Guanshang Technology plans to acquire 100% of Liao Jing Electronics through a combination of stock issuance and cash payment, with the deal expected to create synergies in the defense technology sector [5] Group 6 - Siwei Control announced the termination of its control change planning due to a lack of agreement on core terms, with no significant adverse impact on its business operations [6] - Baihua Pharmaceutical also terminated its control change planning for similar reasons, with no major negative effects on its operations [8] Group 7 - Chaoying Electronics adjusted the investment amount for its AI high-end printed circuit board expansion project from 1.468 billion CNY to 3.315 billion CNY, with a new production capacity target of 166,500 square meters annually [9] Group 8 - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a share buyback commitment, having only bought back 10.0018 million shares out of a planned 20 to 40 million shares [10]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 FF301 2026年1月6日 呈交日期: l. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | IRMB | | | | 本月底結存 | | | 510,476,909 RMB | | 1 RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | 股份類別 | IA | 於香港聯交所上市 ( ...

智通財經APP訊，藥明康德(02359)發佈公告，公司於2026年1月5日收到實際控制人控制的股東發出的 《告知函》，截至2026年1月5日，實際控制人控制的股東通過集中競價和大宗交易方式累計減持公司A 股股份5967.51萬股，佔公司總股本的2%。本次減持計劃已實施完畢。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年1月6日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2026-001 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 无锡药明康德新药开发股份有限公司 股东减持股份结果公告 相关股东保证向公司提供的信息真实、准确、完整，没有虚假记载、 ...